Abstract: In this vortex flowmeter provided with a vortex generator and a flow rate measuring unit, a seal member is mounted on a temperature sensing element including a temperature sensor adhered with an adhesive to a metal temperature sensing case. The temperature sensing element is inserted into a first insertion hole formed in a body case so as to communicate with a body passage. A distal end surface of the temperature sensing element is arranged in either a position where the distal end surface is flush with the passage surface of the body passage formed in the body case or a position more outside than the passage surface in the radial direction of the body passage.

Abstract: In this vortex flowmeter provided with a vortex generator and a flow rate measuring unit the flow rate measurement unit includes a piezoelectric element and a piezoelectric element case. The piezoelectric element case includes: a fitted part fitted in the body case; a pressure receiving part protruding out from a distal end face of the fitted part and placed in a body passage; a hollow portion formed along the axial direction of the piezoelectric element case in the fitted part to separate the fitted part and the pressure receiving part; and a slit formed inside of the pressure receiving part and configured to accommodate the piezoelectric element.

Abstract: In this vortex flowmeter provided with a vortex generator and a flow rate measuring unit, a seal member is mounted on a temperature sensing element including a temperature sensor adhered with an adhesive to a metal temperature sensing case. The temperature sensing element is inserted into a first insertion hole formed in a body case so as to communicate with a body passage. A distal end surface of the temperature sensing element is arranged in either a position where the distal end surface is flush with the passage surface of the body passage formed in the body case or a position more outside than the passage surface in the radial direction of the body passage.

Abstract: In this vortex flowmeter provided with a vortex generator and a flow rate measuring unit the flow rate measurement unit includes a piezoelectric element and a piezoelectric element case. The piezoelectric element case includes: a fitted part fitted in the body case; a pressure receiving part protruding out from a distal end face of the fitted part and placed in a body passage; a hollow portion formed along the axial direction of the piezoelectric element case in the fitted part to separate the fitted part and the pressure receiving part; and a slit formed inside of the pressure receiving part and configured to accommodate the piezoelectric element.

Abstract: A method for reduction of an allyl alcohol-type compound, specific to its allylic hydroxyl group, being carried out without any side reactions such as reduction of other portions of the compound or allylic rearrangement, which comprises treating the compound with trialkylsilane in the presence of AlX.sub.3, wherein X refers to a halogen atom.

Abstract: A novel hydroxamic acid compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof having cell growth inhibition, vascularization inhibition activities and the like.The compounds of the present invention possess inhibitory activities against the growth of vascular endothelial cells and the expression of lymphocyte adhesive factors and the detransforming activity of cells transformed by ras gene, and inhibit the cell growth and are effective on inflammation and tumor.

Abstract: Optically active mono-esters of dicarboxylic acid of the formula III: ##STR1## being useful as intermediates for preparing optically active natural products or medicines; asymmetric synthesis process for preparing thereof being characterized by the reaction of an acid anhydride with an (R)- or (S)-arylacetic acid derivative; and the key substances therefor are also claimed.

Abstract: Optically active mono-esters of dicarboxylic acid of the formula III: ##STR1## being useful as intermediates for preparing optically active natural products or medicines; asymmetric synthesis process for preparing thereof being characterized by the reaction of an acid anhydride with an (R)- or (S)-arylacetic acid derivative; and the key substances therefor are also claimed.

Abstract: Optically active mono-esters of dicarboxylic acid of the formula III: ##STR1## being useful as intermediates for preparing optically active natural products or medicines; asymmetric synthesis process for preparing thereof being characterized by the reaction of an acid anhydride with an (R)- or (S)-arylacetic acid derivative; and the key substances therefor are also claimed.

Abstract: Sulfonylamino substituted bicyclyl hydroxamic acid derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each is hydrogen or lower alkyl; R.sup.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy or halogen; X is alkylene or alkenylene: Y is methylene or oxygen; and n is 0, 1, or 2, or the pharmaceutically acceptable salt thereof. These compounds have an advanced antagonistic activity to thromboxane A.sub.2 (TXA.sub.2)-receptor and are useful for the treatment of thrombosis, vasoconstriction, or bronchoconstriction, and the like disease which are induced by TXA.sub.2.

Abstract: A process for preparing a compound of Formula (I): ##STR1## wherein R' is optionally protected --CH.sub.2 OH or --COOH; R.sup.2 is phenyl or substituted phenyl; and Y is oxygen, methylene, or substituted methylene, which comprises treating a norbornyl acid amide of formula (II): ##STR2## wherein R is optionally protected --CH.sub.2 OH or --COOR.sup.1 ; R.sup.1 is hydrogen or ester-forming group; and Y is oxygen, methylene, or substituted methylene under the reaction conditions for the Hofmann Rearrangement, and then with a substituted sulfonyl halide of formula (III):R.sup.2 SO.sub.2 X (III)wherein R.sup.2 is phenyl or substituted phenyl; and X is halogen atom.

Abstract: An optically active ester of arylacetic acid of the fomula: ##STR1## wherein R.sup.1 is hydrogen or optionally substituted C.sub.1 -C.sub.2 alkyl or phenyl or taken together to from C.sub.2 -C.sub.6 alkylene, or C.sub.2 C.sub.4 -C.sub.6 alkenylene, or bicyclic-ring; R.sup.2 is hydrogen or methyl; X is single bond or Ch.sub.2, C.dbd.O, N--R.sup.4, O, S, CHNHR.sup.4, CHCH.sub.3, CH--Ar, or CHOR.sup.5 (provided that when X is single bond or CH.sub.2, C.dbd.O, N--R.sup.4, O, or S, R.sup.1 and R.sup.2 are not simultaneouly hydrogen or methyl); R.sup.3 is hydrogen, optionally substituted alkyl, or optionally substituted aralkyl; R.sup.4 is hydrogen or amino protecting group; R.sup.5 is hydrogen or hydroxy protecting group; and Ar is optionally substituted aryl; prepared by the reaction of a 94 symmetric acid anhydride with an (R)-or (S)-arylacetic acid derivative in high optical purity; useful as a intermediate for the various optically active natural products and medicines.

Abstract: Optically active mono-esters of dicarboxylic acid of the formula III: ##STR1## being useful as intermediates for preparing optically active natural products or medicines; asymmetric synthesis process for preparing thereof being characterized by the reaction of an acid anhydride with an (R)- or (S)-arylacetic acid derivative; and the key substances therefor are also claimed.

Abstract: Pharmaceutical compounds and compositions for injectable use in the treatment of thromboxane A.sub.2 mediating diseases, comprising a pharmaceutical carrier and a pharmacologically effective amount of a compound of the formula: ##STR1## wherein R.sup.1 is carboxyl or 5-tetrazolyl; R.sup.2 is hydrogen, methyl, hydroxy, chloro, or bromo; or a pharmaceutically acceptable ester or salt thereof, together with one or more non-toxic pharmaceutically acceptable carriers; and methods for treating thromboxane A.sub.2 mediating diseases.

Abstract: Tetrazole derivatives represented by the formula: ##STR1## wherein R is naphthyl or phenyl optionally substituted by phenyl, lower alkyo, halogen, lower alkoxy, hydroxy or acetoxy; X is methylene, dimethylmethylene or oxygen; n is an integer of 0 or 1; and p and r each is an integer of 0 or 1 and q is an integer of 1 or 2 provided that p+q+r=2; or a tautomer in tetrazole ring and a pharmaceutically acceptable salt thereof, which are useful as TXA.sub.2 receptor antagonist.